IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buchwald, U. K.
Right arrow Articles by Pirofski, L.-a.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchwald, U. K.
Right arrow Articles by Pirofski, L.-a.

 Previous Article  |  Next Article 

Infection and Immunity, January 2005, p. 325-333, Vol. 73, No. 1
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.1.325-333.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

A Peptide Mimotope of Type 8 Pneumococcal Capsular Polysaccharide Induces a Protective Immune Response in Mice

Ulrike K. Buchwald,1 Andrew Lees,2,3 Michael Steinitz,4 and Liise-anne Pirofski1,5*

Department of Medicine, Division of Infectious Diseases,1 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York,5 Uniformed Services University, Bethesda,2 Biosynexus, Rockville, Maryland,3 Department of Pathology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel4

Received 24 July 2004/ Returned for modification 1 September 2004/ Accepted 15 September 2004

Increasing antibiotic resistance and a rising patient population at risk for infection due to impaired immunity underscore the importance of vaccination against pneumococci. However, available capsular polysaccharide vaccines are often poorly immunogenic in patients at risk for pneumococcal disease. The goal of this study was to explore the potential of peptide mimotopes to function as alternative vaccine antigens to elicit a type-specific antibody response to pneumococci. We used a human monoclonal immunoglobulin A (IgA) antibody (NAD) to type 8 Streptococcus pneumoniae capsular polysaccharide (type 8 PS) to screen a phage display library, and the phage PUB1 displaying the peptide FHLPYNHNWFAL was selected after three rounds of biopanning. Inhibition studies with phage-displayed peptide or the peptide PUB1 and type 8 PS showed that PUB1 is a mimetic of type 8 PS. PUB1 conjugated to tetanus toxoid (PUB1-TT) induced a type 8 PS-specific antibody response in BALB/c mice, further defining it as a mimotope of type 8 PS. The administration of immune sera obtained from PUB1-TT-immunized mice earlier (days 14 and 21) and later (days 87 and 100) after primary and reimmunization resulted in a highly significant prolongation of the survival of naive mice after pneumococcal challenge compared to controls. The survival of PUB1-TT-immunized mice was also prolonged after pneumococcal challenge nearly 4 months after primary immunization. The efficacy of PUB1-TT-induced immune sera provides proof of principle that a mimotope-induced antibody response can protect against pneumococci and suggests that peptide mimotopes selected by type-specific human antibodies could hold promise as immunogens for pneumococci.


* Corresponding author. Mailing address: Albert Einstein College of Medicine, Division of Infectious Diseases, Room 709 Forchheimer Bldg., 1300 Morris Park Ave., Bronx, NY 10461. Phone: (718) 430-2372. Fax: (718) 430-2292. E-mail: pirofski{at}aecom.yu.edu.

Editor: J. N. Weiser


Infection and Immunity, January 2005, p. 325-333, Vol. 73, No. 1
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.1.325-333.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2005 by the American Society for Microbiology. All rights reserved.